Dr. Daniel J. Haraf on a Less Toxic Treatment for Patients With Head and Neck Cancer
Haraf says historically, medical professionals have treated patients with radiation therapy "from their eyebrows to their collarbones." This approach, while effective, has resulted in an abundance of toxicities.
Daniel J. Haraf, MD, professor of Radiation & Cellular Oncology, medical Director, Radiation Oncology, The University of Chicago Medicine, discusses a more focused approach to radiation therapy in head and neck cancer. Haraf says historically, medical professionals have treated patients with radiation therapy "from their eyebrows to their collarbones." This approach, while effective, has resulted in an abundance of toxicities.
Haraf said a recent study shows that an approach of induction chemotherapy utilized in 100 patients, without any elective nodal radiation, resulted in a positive response for 99 of the 100 patients. Haraf said these results are "practice changing" and could result in confined radiotherapy with less toxicities.
Advancing Neoadjuvant Therapy for HER2+ Breast Cancer Through ctDNA Monitoring
December 19th 2024In an interview with Targeted Oncology, Adrienne Waks, MD, provided insights into the significance of the findings from the DAPHNe trial and their clinical implications for patients with HER2-positive breast cancer.
Read More
AI-Driven Deep Learning Model Shows Promise in Standardizing MDS Diagnosis
December 10th 2024In an interview, Palak Dave discussed how artificial intelligence, using deep learning to analyze bone marrow aspirate smear images, could standardize and accelerate the diagnosis of MDS vs pre-MDS conditions.
Read More
Systemic Therapy Choice Linked to Radiosurgery Outcomes in Brain Mets
December 6th 2024In an interview with Targeted OncologyT, Rupesh Kotecha, MD, discussed a study focused on how systemic therapy selection impacts outcomes in patients with brain metastases, particularly those with lung cancer.
Read More
